UCB Consensus

Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of over 15 different brokers. See the list of analysts and their contact details here.

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.

ucb

UCB HY2019 P&L Consensus

In € million	HY 2019e Average	HY 2019e Median
Revenue	2,302	2,308
Recurring EBIT	573	561
Recurring EBITDA	696	702
Net Profit*	420	411
Core EPS	2.49	2.51

*attributable to UCB shareholders

UCB HY2019 Product Sales Consensus

In € million	HY 2019e Average	HY 2019e Median
Cimzia	736	737
Vimpat	606	608
Keppra	385	384
Briviact	98	99
Neupro	156	153

UCB FY Consensus Product Sales Estimates (Average)

In € million	2018a	2019e	2020e	2021e	2022e	2023e	2024e
Core Products
Cimzia	1,446	1,515	1,537	1,550	1,543	1,506	1,439
Vimpat	1,099	1,230	1,329	1,422	1,248	850	693
Keppra	790	758	723	662	615	575	546
Briviact	142	217	286	355	414	471	513
Neupro	321	326	325	288	231	196	154
6 Potential new Product Launches* (global sales, non-risk adj.)
Evenity (romosozumab)	0	38	105	192	279	365	460
Midazolam nasal spray	0	9	23	42	60	79	92
Bimekizumab	0	0	9	66	189	355	526
Rozanolixizumab (Rozimab/Roza)	0	0	0	9	42	125	218
Padsevonil	0	0	3	12	37	90	146
Anti-Tau	0	0	0	0	0	50	125

*in the next 5 years

UCB FY Consensus Earnings Estimates (Average)

In € million	2018a	2019e	2020e	2021e
Net Sales	4,412	4,505	4,715	4,888
Revenue	4,632	4,699	4,899	5,069
Recurring EBIT	1,105	1,046	1,154	1,280
Recurring EBITDA	1,398	1,327	1,436	1,560
Net Profit*	800	757	843	955
Core EPS (€)	4.78	4.62	5.08	5.68

_{*attributable to UCB shareholders}

UCB FY Consensus Product Sales Estimates (Median)

In € million	2018a	2019e	2020e	2021e	2022e	2023e	2024e
Core Products
Cimzia	1,446	1,516	1,553	1,559	1,554	1,537	1,401
Vimpat	1,099	1,238	1,334	1,413	1,236	843	710
Keppra	790	752	721	653	605	568	539
Briviact	142	214	297	372	429	474	531
Neupro	321	326	322	285	216	176	140
6 Potential new Product Launches* (global sales, non-risk adj.)
Evenity (romosozumab)	0	37	95	173	252	313	373
Midazolam nasal spray	0	10	20	40	65	80	96
Bimekizumab	0	0	0	50	150	350	520
Rozanolixizumab (Rozimab/Roza)	0	0	0	0	12	105	219
Padsevonil	0	0	0	0	20	80	153
Anti-Tau	0	0	0	0	0	50	125

_{*in the next 5 years}

UCB FY Consensus Earnings Estimates (Median)

In € million	2018a	2019e	2020e	2021e
Net Sales	4,412	4,516	4,740	4,945
Revenue	4,632	4,699	4,910	5,125
Recurring EBIT	1,105	1,045	1,157	1,280
Recurring EBITDA	1,398	1,334	1,445	1,563
Net Profit*	800	754	847	956
Core EPS (€)	4.78	4.65	5.10	5.69

*attributable to UCB shareholders

Downloads:
UCB FY & HY 2019 Consensus (Excel)
UCB HY 2019 Consensus (PDF)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 16 July, 2019

Check out UCB's new IR Apps:

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.